丹麦卡介苗与口服脊髓灰质炎疫苗对印度体重低于2000克新生儿死亡率的影响:多中心开放标签随机对照试验(BLOW2)
BLOW2是一项在印度东南部三个三级NICU开展的多中心开放标签随机对照试验,纳入5420名体重<2000克的新生儿,1:1随机分为早期接种组(入院48小时内皮内接种0.1 mL丹麦卡介苗加口服脊髓灰质炎疫苗)和对照组(延迟至出院时接种)。早期接种组新生儿死亡238例(8.8%),对照组273例(10.1%);按NICU分层并校正出生后日龄、出生体重、性别和胎龄后,调整HR 0.83(95%CI 0.69-0.98;P=0.03),NNT为21(95%CI 10-245)。感染相关新生儿死亡率人年值早期接种组0.40 vs 对照组0.73(调整HR 0.53,95%CI 0.40-0.70)。无结核死亡,未观察到与接种相关的严重不良反应。
要点
- 体重<2000克NICU新生儿入院48小时内接种丹麦卡介苗加口服脊髓灰质炎疫苗,全因新生儿死亡率8.8% vs 对照组10.1%(调整HR 0.83,95%CI 0.69-0.98;P=0.03)。
- 预防一例死亡需治疗人数NNT为21(95%CI 10-245)。
- 感染相关新生儿死亡率人年值早期接种组0.40 vs 对照组0.73(调整HR 0.53,95%CI 0.40-0.70)。
- 无结核死亡发生,未观察到与接种相关的严重不良反应。
- 作者认为,在高死亡率地区由熟练操作者于出生当天或出生后不久为高比例新生儿接种,可大幅降低新生儿死亡率。
适用人群与场景
- 印度东南部三个三级NICU收治的体重<2000克新生儿,随机时中位日龄0.9天,中位出生体重1560克。
处置流程与药物剂量
- 早期接种组:入院48小时内皮内接种0.1 mL丹麦卡介苗加口服脊髓灰质炎疫苗。
- 对照组:延迟至至少出院时接种丹麦卡介苗加口服脊髓灰质炎疫苗。
- 随机按NICU、性别和出生体重(<1000克、1000-1499克、1500-1999克)分层。
研究设计与关键结果
- 多中心、开放标签、随机对照试验,三个三级NICU,7067名新生儿评估合格,5420名随机(早期接种组2714名,对照组2706名),9例失访。
- 主要终点全因新生儿死亡率:早期接种组238/2714(8.8%)vs 对照组273/2706(10.1%);按NICU分层并校正出生后日龄、出生体重、性别和胎龄后,调整HR 0.83(95%CI 0.69-0.98;P=0.03),NNT 21(95%CI 10-245)。
- 主要次要终点感染相关新生儿死亡率(试验进行约三分之一时纳入):人年值早期接种组0.40 vs 对照组0.73,调整HR 0.53(95%CI 0.40-0.70)。
- 无结核死亡发生,未观察到与接种相关的严重不良反应。
证据类型、等级与局限
- 证据类型:多中心开放标签随机对照试验。
- 试验注册:Clinical Trials Registry India CTRI/2017/01/007676。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在高死亡率地区由熟练操作者于出生当天或出生后不久为高比例新生儿接种,可大幅降低新生儿死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To test the effect on all cause neonatal mortality (aged ≤28 days) of a dose of BCG Danish vaccine and oral polio vaccine (OPV) administered to newborn babies weighing <2000 g.
DESIGN: Multicentre, open label, randomised controlled trial SETTING: Three tertiary neonatal intensive care units (NICUs) in southeast India.
POPULATION: Newborn babies weighing <2000 g. 7067 were assessed for eligibility and 5420 were randomised (2714 BCG-OPV, 2706 control).
INTERVENTIONS: Newborns were randomised 1:1 to receive 0.1 mL of BCG Danish intradermally plus OPV, either within 48 hours of admission to the NICU (early vaccination group) or delayed until at least the time of discharge (control group). Stratification was by NICU, sex, and birth weight (<1000 g, 1000-1499 g, 1500-1999 g).
MAIN OUTCOME MEASURES: The primary outcome was all cause neonatal mortality. The main secondary outcome, included a third of the way through the trial, was neonatal mortality due to infection.
RESULTS: Of the 5420 newborn babies randomised at a median age of 0.9 days and with a median birth weight of 1560 g, nine were lost to follow-up. Deaths occurred in 238 (8.8%) of 2714 newborn babies in the early vaccination group and 273 (10.1%) of 2706 in the control group. In intention-to-treat Cox survival analysis stratified by NICU and adjusted for postnatal age, birth weight, sex, and gestational age, neonatal mortality per person year was 1.29 in the early vaccination group and 1.50 in the control group (adjusted hazard ratio 0.83, 95% confidence interval (CI) 0.69 to 0.98; P=0.03). The number needed to treat to prevent one death was 21 (95% CI 10 to 245). Infection related neonatal mortality per person year was 0.40 in the early vaccination group and 0.73 in the control group (adjusted hazard ratio 0.53, 95% CI 0.40 to 0.70). No deaths from tuberculosis occurred, and no serious adverse effects were associated with vaccination.
CONCLUSIONS: In newborn babies weighing <2000 g in intensive care, BCG-OPV administered at a median age of 0.9 days reduced all cause neonatal mortality owing to a decrease in deaths due to infections other than tuberculosis (a non-specific or off-target effect). A substantial reduction in neonatal mortality could be achieved if a skilled administrator vaccinated a high proportion of newborn babies in high mortality settings on the day of, or soon after, birth.
TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2017/01/007676.
参考来源
- Adhisivam B, Kamalarathnam C, Bhat BV, et al. Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2). BMJ. 2025. PMID: 40983468. doi:10.1136/bmj-2025-084745
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。